ArticleNeuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater2026
Management challenges in delirium in genetically confirmed long QT syndrome: a case report and discussion.
Article in Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreating delirium in adolescents with congenital long QT syndrome (LQTS) demands agents that do not aggravate ventricular repolarisation. A 15-year-old girl with genetically confirmed LQT1 and newly diagnosed acute lymphoblastic leukaemia developed hyperactive delirium in the paediatric intensive care unit after sepsis, abdominal surgery and prolonged sedation. Baseline manually calculated QTc in lead II was 533 ms (Bazett), 500 ms (Framingham), and 489 ms (Fridericia). Standard antipsychotics were avoided owing to torsadogenic risk. Low-dose aripiprazole (2 mg p.o. initially, up to 2 mg every 2 h as needed) was introduced, with twice-daily 12-lead ECGs. Agitation resolved within 48 h; QTc fluctuated between 460 and 490 ms (all three formulas) without ventricular arrhythmia. Serial serum aripiprazole levels were monitored for toxicity during intermittent dosing (cumulative dose 42 mg over 6 days). No extrapyramidal or haemodynamic adverse effects occurred, and aripiprazole was discontinued after a further 8 days.
conclusionThis case illustrates a structured approach to delirium in adolescent LQTS and supports aripiprazole as a pragmatic option when QT-prolonging antipsychotics are contraindicated.
Indexed as
Identifiers
41571907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.